Gary A Lyons - Net Worth and Insider Trading
Gary A Lyons Net Worth
The estimated net worth of Gary A Lyons is at least $27 Million dollars as of 2024-04-26. Gary A Lyons is the Director of Neurocrine Biosciences Inc and owns about 193,697 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $27 Million. Gary A Lyons is also the Director of Fresh Tracks Therapeutics Inc and owns about 25 shares of Fresh Tracks Therapeutics Inc (FRTX) stock worth over $23. Details can be seen in Gary A Lyons's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Gary A Lyons has not made any transactions after 2023-12-22 and currently still holds the listed stock(s).
Transaction Summary of Gary A Lyons
Gary A Lyons Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Gary A Lyons owns 10 companies in total, including Fresh Tracks Therapeutics Inc (FRTX) , Eledon Pharmaceuticals Inc (ELDN) , and Neurocrine Biosciences Inc (NBIX) among others .
Click here to see the complete history of Gary A Lyons’s form 4 insider trades.
Insider Ownership Summary of Gary A Lyons
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| FRTX | Fresh Tracks Therapeutics Inc | 2021-06-14 | director |
| ELDN | Eledon Pharmaceuticals Inc | 2017-05-10 | director |
| NBIX | Neurocrine Biosciences Inc | 2023-12-22 | director & President and CEO |
| RIGL | Rigel Pharmaceuticals Inc | 2022-05-20 | director |
| TVTX | Travere Therapeutics Inc | 2014-10-08 | director |
| PSTV | Plus Therapeutics Inc | 2013-10-07 | director |
| HGENQ | Humanigen Inc | 2012-08-11 | director |
| NGSX | NeurogesX Inc | 2012-06-07 | director |
| PARD | Poniard Pharmaceuticals Inc | 2011-07-11 | director |
| PDLI | PDL BioPharma Inc | 2008-08-13 | director |
Gary A Lyons Latest Holdings Summary
Gary A Lyons currently owns a total of 2 stocks. Among these stocks, Gary A Lyons owns 193,697 shares of Neurocrine Biosciences Inc (NBIX) as of December 22, 2023, with a value of $27 Million and a weighting of 100%. Gary A Lyons also owns 25 shares of Fresh Tracks Therapeutics Inc (FRTX) as of December 5, 2016, with a value of $23 and a weighting of 0%.
Latest Holdings of Gary A Lyons
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | 2023-12-22 | 193,697 | 137.76 | 26,683,699 |
| FRTX | Fresh Tracks Therapeutics Inc | 2016-12-05 | 25 | 0.92 | 23 |
Holding Weightings of Gary A Lyons
Gary A Lyons Form 4 Trading Tracker
According to the SEC Form 4 filings, Gary A Lyons has made a total of 13 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Neurocrine Biosciences Inc is the sale of 10,000 shares on December 22, 2023, which brought Gary A Lyons around $1 Million.
According to the SEC Form 4 filings, Gary A Lyons has made a total of 0 transactions in Fresh Tracks Therapeutics Inc (FRTX) over the past 5 years. The most-recent trade in Fresh Tracks Therapeutics Inc is the sale of 22 shares on December 5, 2016, which brought Gary A Lyons around $16,279.
Insider Trading History of Gary A Lyons
- 1
Gary A Lyons Trading Performance
GuruFocus tracks the stock performance after each of Gary A Lyons's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gary A Lyons is -17.48%. GuruFocus also compares Gary A Lyons's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gary A Lyons within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Gary A Lyons's insider trading performs compared to the benchmark.
Performance of Gary A Lyons
Average Return
-29.87%
Outperforming Transactions
33%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.91 | -17.48 | -39.35 | -29.87 | -40.94 | -41.46 |
| Relative Return to S&P 500(%) | 1.66 | -21.31 | -46.18 | -48.62 | -56.84 | -52.81 |
Gary A Lyons Ownership Network
Ownership Network List of Gary A Lyons
Ownership Network Relation of Gary A Lyons
Gary A Lyons Owned Company Details
What does Fresh Tracks Therapeutics Inc do?
Who are the key executives at Fresh Tracks Therapeutics Inc?
Gary A Lyons is the director of Fresh Tracks Therapeutics Inc. Other key executives at Fresh Tracks Therapeutics Inc include Chief Medical Officer Monica E. Luchi , director & CHAIRMAN OF THE BOARD Reginald L Hardy , and General Counsel and CCO David R. Mcavoy .
Fresh Tracks Therapeutics Inc (FRTX) Insider Trades Summary
Over the past 18 months, Gary A Lyons made no insider transaction in Fresh Tracks Therapeutics Inc (FRTX). Other recent insider transactions involving Fresh Tracks Therapeutics Inc (FRTX) include a net sale of 110 shares made by ,
In summary, during the past 3 months, insiders sold 0 shares of Fresh Tracks Therapeutics Inc (FRTX) in total and bought 210,807 shares, with a net purchase of 210,807 shares. During the past 18 months, 110 shares of Fresh Tracks Therapeutics Inc (FRTX) were sold and 407,807 shares were bought by its insiders, resulting in a net purchase of 407,697 shares.
Fresh Tracks Therapeutics Inc (FRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Fresh Tracks Therapeutics Inc Insider Transactions
Gary A Lyons Mailing Address
Above is the net worth, insider trading, and ownership report for Gary A Lyons. You might contact Gary A Lyons via mailing address: 12790 El Camino Real, C/o Neurocrine Biosciences, San Diego Ca 92130.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
